Alto Neuroscience (ANRO) Change in Account Payables (2023 - 2026)

Alto Neuroscience has reported Change in Account Payables for 4 years, with the latest figure at $1.5 million in Q1 2026.

• Quarterly Change in Account Payables rose 660.15% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (up 327.24% YoY) and the FY2025 annual result came in at $221000.0, down 57.17% from the prior year.
• Change in Account Payables improved to $1.5 million in Q1 2026 per ANRO's latest filing, from -$297000.0 in the prior quarter.
• Over five years, Change in Account Payables peaked at $1.5 million in Q1 2026 and troughed at -$781000.0 in Q4 2023.
• A 4-year average of $122692.3 and a median of -$251000.0 in 2024 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2025 and 2026: Change in Account Payables sank 123.75% in 2025, then soared 660.15% in 2026.
• Over 4 years, Change in Account Payables stood at -$781000.0 in 2023, then grew by 2.43% to -$762000.0 in 2024, then surged by 61.02% to -$297000.0 in 2025, then soared by 601.68% to $1.5 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered $1.5 million, -$297000.0, and $461000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.